nodes	percent_of_prediction	percent_of_DWPC	metapath
Solifenacin—Benazepril—Lisinopril—dilated cardiomyopathy	0.862	1	CrCrCtD
Solifenacin—Hyperkalaemia—Spironolactone—dilated cardiomyopathy	0.00352	0.0401	CcSEcCtD
Solifenacin—Benazepril—ACE—dilated cardiomyopathy	0.00277	1	CrCbGaD
Solifenacin—Drug interaction—Furosemide—dilated cardiomyopathy	0.0021	0.0239	CcSEcCtD
Solifenacin—Renal failure—Spironolactone—dilated cardiomyopathy	0.00197	0.0224	CcSEcCtD
Solifenacin—Bladder pain—Furosemide—dilated cardiomyopathy	0.00176	0.0201	CcSEcCtD
Solifenacin—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.0017	0.0194	CcSEcCtD
Solifenacin—Drug interaction—Lisinopril—dilated cardiomyopathy	0.00157	0.018	CcSEcCtD
Solifenacin—Dermatitis exfoliative—Furosemide—dilated cardiomyopathy	0.0015	0.0171	CcSEcCtD
Solifenacin—Hyperkalaemia—Lisinopril—dilated cardiomyopathy	0.00143	0.0164	CcSEcCtD
Solifenacin—Cystitis noninfective—Lisinopril—dilated cardiomyopathy	0.00143	0.0163	CcSEcCtD
Solifenacin—Cystitis—Lisinopril—dilated cardiomyopathy	0.00141	0.0161	CcSEcCtD
Solifenacin—Urinary retention—Furosemide—dilated cardiomyopathy	0.00134	0.0153	CcSEcCtD
Solifenacin—Bladder pain—Lisinopril—dilated cardiomyopathy	0.00132	0.0151	CcSEcCtD
Solifenacin—Confusional state—Spironolactone—dilated cardiomyopathy	0.00129	0.0147	CcSEcCtD
Solifenacin—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00128	0.0146	CcSEcCtD
Solifenacin—Muscular weakness—Furosemide—dilated cardiomyopathy	0.00125	0.0142	CcSEcCtD
Solifenacin—Somnolence—Spironolactone—dilated cardiomyopathy	0.00113	0.0129	CcSEcCtD
Solifenacin—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.00112	0.0128	CcSEcCtD
Solifenacin—Renal impairment—Lisinopril—dilated cardiomyopathy	0.00111	0.0127	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.0011	0.0126	CcSEcCtD
Solifenacin—Renal failure—Furosemide—dilated cardiomyopathy	0.00107	0.0122	CcSEcCtD
Solifenacin—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00105	0.012	CcSEcCtD
Solifenacin—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00103	0.0117	CcSEcCtD
Solifenacin—Urticaria—Spironolactone—dilated cardiomyopathy	0.00101	0.0116	CcSEcCtD
Solifenacin—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.000965	0.011	CcSEcCtD
Solifenacin—Urethral disorder—Furosemide—dilated cardiomyopathy	0.000958	0.0109	CcSEcCtD
Solifenacin—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00094	0.0107	CcSEcCtD
Solifenacin—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.000924	0.0105	CcSEcCtD
Solifenacin—Influenza—Lisinopril—dilated cardiomyopathy	0.000916	0.0104	CcSEcCtD
Solifenacin—Eye disorder—Furosemide—dilated cardiomyopathy	0.000914	0.0104	CcSEcCtD
Solifenacin—Pruritus—Spironolactone—dilated cardiomyopathy	0.000903	0.0103	CcSEcCtD
Solifenacin—Angiopathy—Furosemide—dilated cardiomyopathy	0.000887	0.0101	CcSEcCtD
Solifenacin—Immune system disorder—Furosemide—dilated cardiomyopathy	0.000883	0.0101	CcSEcCtD
Solifenacin—Dysuria—Lisinopril—dilated cardiomyopathy	0.000857	0.00977	CcSEcCtD
Solifenacin—Malnutrition—Furosemide—dilated cardiomyopathy	0.000851	0.0097	CcSEcCtD
Solifenacin—Dizziness—Spironolactone—dilated cardiomyopathy	0.000844	0.00963	CcSEcCtD
Solifenacin—Dysgeusia—Furosemide—dilated cardiomyopathy	0.000833	0.0095	CcSEcCtD
Solifenacin—Depression—Lisinopril—dilated cardiomyopathy	0.000815	0.00929	CcSEcCtD
Solifenacin—Vomiting—Spironolactone—dilated cardiomyopathy	0.000812	0.00926	CcSEcCtD
Solifenacin—Rash—Spironolactone—dilated cardiomyopathy	0.000805	0.00918	CcSEcCtD
Solifenacin—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000804	0.00917	CcSEcCtD
Solifenacin—Renal failure—Lisinopril—dilated cardiomyopathy	0.000803	0.00916	CcSEcCtD
Solifenacin—Vision blurred—Furosemide—dilated cardiomyopathy	0.000802	0.00914	CcSEcCtD
Solifenacin—Headache—Spironolactone—dilated cardiomyopathy	0.0008	0.00912	CcSEcCtD
Solifenacin—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.000794	0.00906	CcSEcCtD
Solifenacin—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.000773	0.00881	CcSEcCtD
Solifenacin—Nausea—Spironolactone—dilated cardiomyopathy	0.000758	0.00865	CcSEcCtD
Solifenacin—Hallucination—Lisinopril—dilated cardiomyopathy	0.00073	0.00832	CcSEcCtD
Solifenacin—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.000728	0.0083	CcSEcCtD
Solifenacin—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.000724	0.00826	CcSEcCtD
Solifenacin—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.000723	0.00824	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.000719	0.0082	CcSEcCtD
Solifenacin—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.000719	0.0082	CcSEcCtD
Solifenacin—Dry mouth—Furosemide—dilated cardiomyopathy	0.000709	0.00808	CcSEcCtD
Solifenacin—Confusional state—Furosemide—dilated cardiomyopathy	0.0007	0.00799	CcSEcCtD
Solifenacin—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.000694	0.00792	CcSEcCtD
Solifenacin—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.000693	0.00791	CcSEcCtD
Solifenacin—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000681	0.00777	CcSEcCtD
Solifenacin—Skin disorder—Furosemide—dilated cardiomyopathy	0.000675	0.00769	CcSEcCtD
Solifenacin—Angiopathy—Lisinopril—dilated cardiomyopathy	0.000665	0.00759	CcSEcCtD
Solifenacin—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.000661	0.00754	CcSEcCtD
Solifenacin—Mental disorder—Lisinopril—dilated cardiomyopathy	0.000643	0.00733	CcSEcCtD
Solifenacin—Malnutrition—Lisinopril—dilated cardiomyopathy	0.000638	0.00728	CcSEcCtD
Solifenacin—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.000625	0.00713	CcSEcCtD
Solifenacin—Somnolence—Furosemide—dilated cardiomyopathy	0.000617	0.00704	CcSEcCtD
Solifenacin—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000604	0.00688	CcSEcCtD
Solifenacin—Vision blurred—Lisinopril—dilated cardiomyopathy	0.000602	0.00686	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.0006	0.00684	CcSEcCtD
Solifenacin—Fatigue—Furosemide—dilated cardiomyopathy	0.000599	0.00683	CcSEcCtD
Solifenacin—Constipation—Furosemide—dilated cardiomyopathy	0.000594	0.00677	CcSEcCtD
Solifenacin—Angioedema—Lisinopril—dilated cardiomyopathy	0.000583	0.00665	CcSEcCtD
Solifenacin—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.000572	0.00653	CcSEcCtD
Solifenacin—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000568	0.00648	CcSEcCtD
Solifenacin—Palpitations—Lisinopril—dilated cardiomyopathy	0.000564	0.00643	CcSEcCtD
Solifenacin—Cough—Lisinopril—dilated cardiomyopathy	0.000557	0.00635	CcSEcCtD
Solifenacin—Urticaria—Furosemide—dilated cardiomyopathy	0.000552	0.00629	CcSEcCtD
Solifenacin—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000549	0.00626	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00054	0.00616	CcSEcCtD
Solifenacin—Dry mouth—Lisinopril—dilated cardiomyopathy	0.000532	0.00606	CcSEcCtD
Solifenacin—Confusional state—Lisinopril—dilated cardiomyopathy	0.000525	0.00599	CcSEcCtD
Solifenacin—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.000521	0.00594	CcSEcCtD
Solifenacin—Infection—Lisinopril—dilated cardiomyopathy	0.000518	0.0059	CcSEcCtD
Solifenacin—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000512	0.00583	CcSEcCtD
Solifenacin—Tachycardia—Lisinopril—dilated cardiomyopathy	0.000509	0.0058	CcSEcCtD
Solifenacin—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000506	0.00577	CcSEcCtD
Solifenacin—Asthenia—Furosemide—dilated cardiomyopathy	0.000498	0.00568	CcSEcCtD
Solifenacin—Pruritus—Furosemide—dilated cardiomyopathy	0.000491	0.0056	CcSEcCtD
Solifenacin—Somnolence—Lisinopril—dilated cardiomyopathy	0.000463	0.00528	CcSEcCtD
Solifenacin—Dizziness—Furosemide—dilated cardiomyopathy	0.000459	0.00524	CcSEcCtD
Solifenacin—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000459	0.00523	CcSEcCtD
Solifenacin—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000453	0.00517	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00045	0.00513	CcSEcCtD
Solifenacin—Fatigue—Lisinopril—dilated cardiomyopathy	0.000449	0.00512	CcSEcCtD
Solifenacin—Constipation—Lisinopril—dilated cardiomyopathy	0.000446	0.00508	CcSEcCtD
Solifenacin—Vomiting—Furosemide—dilated cardiomyopathy	0.000442	0.00504	CcSEcCtD
Solifenacin—Rash—Furosemide—dilated cardiomyopathy	0.000438	0.00499	CcSEcCtD
Solifenacin—Dermatitis—Furosemide—dilated cardiomyopathy	0.000437	0.00499	CcSEcCtD
Solifenacin—Headache—Furosemide—dilated cardiomyopathy	0.000435	0.00496	CcSEcCtD
Solifenacin—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000429	0.0049	CcSEcCtD
Solifenacin—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000426	0.00486	CcSEcCtD
Solifenacin—Urticaria—Lisinopril—dilated cardiomyopathy	0.000414	0.00472	CcSEcCtD
Solifenacin—Nausea—Furosemide—dilated cardiomyopathy	0.000413	0.0047	CcSEcCtD
Solifenacin—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000412	0.0047	CcSEcCtD
Solifenacin—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000384	0.00438	CcSEcCtD
Solifenacin—Asthenia—Lisinopril—dilated cardiomyopathy	0.000374	0.00426	CcSEcCtD
Solifenacin—Pruritus—Lisinopril—dilated cardiomyopathy	0.000369	0.0042	CcSEcCtD
Solifenacin—Dizziness—Lisinopril—dilated cardiomyopathy	0.000345	0.00393	CcSEcCtD
Solifenacin—Vomiting—Lisinopril—dilated cardiomyopathy	0.000331	0.00378	CcSEcCtD
Solifenacin—Rash—Lisinopril—dilated cardiomyopathy	0.000329	0.00375	CcSEcCtD
Solifenacin—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000328	0.00374	CcSEcCtD
Solifenacin—Headache—Lisinopril—dilated cardiomyopathy	0.000326	0.00372	CcSEcCtD
Solifenacin—Nausea—Lisinopril—dilated cardiomyopathy	0.00031	0.00353	CcSEcCtD
Solifenacin—CHRM5—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.00012	0.00255	CbGpPWpGaD
Solifenacin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.00012	0.00254	CbGpPWpGaD
Solifenacin—CHRM1—Regulation of Actin Cytoskeleton—RAC1—dilated cardiomyopathy	0.000119	0.00252	CbGpPWpGaD
Solifenacin—CHRM3—Regulation of Actin Cytoskeleton—RAC1—dilated cardiomyopathy	0.000119	0.00251	CbGpPWpGaD
Solifenacin—CHRM4—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000118	0.0025	CbGpPWpGaD
Solifenacin—CHRM2—Regulation of Actin Cytoskeleton—RAC1—dilated cardiomyopathy	0.000118	0.00249	CbGpPWpGaD
Solifenacin—CHRM4—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.000117	0.00248	CbGpPWpGaD
Solifenacin—CHRM4—Regulation of Actin Cytoskeleton—RAF1—dilated cardiomyopathy	0.000117	0.00248	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000117	0.00247	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000116	0.00246	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000116	0.00246	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000116	0.00245	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000116	0.00245	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000115	0.00243	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000115	0.00243	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000113	0.00239	CbGpPWpGaD
Solifenacin—CHRM5—Regulation of Actin Cytoskeleton—RAF1—dilated cardiomyopathy	0.000112	0.00237	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000108	0.00228	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000108	0.00228	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000107	0.00226	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000105	0.00221	CbGpPWpGaD
Solifenacin—CHRM1—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000104	0.00221	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000104	0.00221	CbGpPWpGaD
Solifenacin—CHRM3—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000104	0.0022	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000103	0.00218	CbGpPWpGaD
Solifenacin—CHRM2—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000103	0.00218	CbGpPWpGaD
Solifenacin—CHRM4—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000101	0.00213	CbGpPWpGaD
Solifenacin—CHRM1—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	9.88e-05	0.00209	CbGpPWpGaD
Solifenacin—CHRM3—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	9.85e-05	0.00209	CbGpPWpGaD
Solifenacin—CHRM2—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	9.76e-05	0.00207	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—AGTR1—dilated cardiomyopathy	9.65e-05	0.00204	CbGpPWpGaD
Solifenacin—CHRM4—GPCR ligand binding—ADRB2—dilated cardiomyopathy	9.56e-05	0.00202	CbGpPWpGaD
Solifenacin—CHRM1—Circadian rythm related genes—FAS—dilated cardiomyopathy	9.56e-05	0.00202	CbGpPWpGaD
Solifenacin—CHRM1—G alpha (q) signalling events—AGT—dilated cardiomyopathy	9.48e-05	0.00201	CbGpPWpGaD
Solifenacin—CHRM3—G alpha (q) signalling events—AGT—dilated cardiomyopathy	9.45e-05	0.002	CbGpPWpGaD
Solifenacin—CHRM4—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	9.31e-05	0.00197	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—ADRB2—dilated cardiomyopathy	9.16e-05	0.00194	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	8.92e-05	0.00189	CbGpPWpGaD
Solifenacin—CHRM5—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	8.92e-05	0.00189	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	8.9e-05	0.00188	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—AGTR2—dilated cardiomyopathy	8.84e-05	0.00187	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—CXCL2—dilated cardiomyopathy	8.84e-05	0.00187	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—CXCL2—dilated cardiomyopathy	8.81e-05	0.00187	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—AGTR2—dilated cardiomyopathy	8.81e-05	0.00187	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	8.81e-05	0.00187	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—AGTR2—dilated cardiomyopathy	8.72e-05	0.00185	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—CXCL2—dilated cardiomyopathy	8.72e-05	0.00185	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—ANKRD1—dilated cardiomyopathy	8.53e-05	0.00181	CbGpPWpGaD
Solifenacin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	8.48e-05	0.0018	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	8.47e-05	0.00179	CbGpPWpGaD
Solifenacin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	8.45e-05	0.00179	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	8.44e-05	0.00179	CbGpPWpGaD
Solifenacin—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	8.36e-05	0.00177	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	8.36e-05	0.00177	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	8.22e-05	0.00174	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—CXCR3—dilated cardiomyopathy	8.19e-05	0.00173	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—CXCR3—dilated cardiomyopathy	8.11e-05	0.00172	CbGpPWpGaD
Solifenacin—CHRM4—Regulation of Actin Cytoskeleton—EGFR—dilated cardiomyopathy	8.03e-05	0.0017	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—TAZ—dilated cardiomyopathy	8.02e-05	0.0017	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—ADRB1—dilated cardiomyopathy	7.96e-05	0.00169	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—ADRB1—dilated cardiomyopathy	7.93e-05	0.00168	CbGpPWpGaD
Solifenacin—CHRM1—Regulation of Actin Cytoskeleton—RAF1—dilated cardiomyopathy	7.89e-05	0.00167	CbGpPWpGaD
Solifenacin—CHRM3—Regulation of Actin Cytoskeleton—RAF1—dilated cardiomyopathy	7.87e-05	0.00167	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—ADRB1—dilated cardiomyopathy	7.86e-05	0.00166	CbGpPWpGaD
Solifenacin—CHRM2—G alpha (i) signalling events—AGT—dilated cardiomyopathy	7.8e-05	0.00165	CbGpPWpGaD
Solifenacin—CHRM2—Regulation of Actin Cytoskeleton—RAF1—dilated cardiomyopathy	7.79e-05	0.00165	CbGpPWpGaD
Solifenacin—CHRM5—Regulation of Actin Cytoskeleton—EGFR—dilated cardiomyopathy	7.69e-05	0.00163	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	7.41e-05	0.00157	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	7.41e-05	0.00157	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—SDHA—dilated cardiomyopathy	7.26e-05	0.00154	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	7.09e-05	0.0015	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	7.09e-05	0.0015	CbGpPWpGaD
Solifenacin—CHRM4—GPCR ligand binding—AGT—dilated cardiomyopathy	7.09e-05	0.0015	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	6.89e-05	0.00146	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—AGTR1—dilated cardiomyopathy	6.8e-05	0.00144	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—AGT—dilated cardiomyopathy	6.79e-05	0.00144	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—AGTR1—dilated cardiomyopathy	6.77e-05	0.00143	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—AGTR2—dilated cardiomyopathy	6.73e-05	0.00142	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—CXCL2—dilated cardiomyopathy	6.73e-05	0.00142	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—AGTR1—dilated cardiomyopathy	6.71e-05	0.00142	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	6.67e-05	0.00141	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	6.59e-05	0.0014	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	6.45e-05	0.00137	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—AGTR2—dilated cardiomyopathy	6.44e-05	0.00136	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—CXCL2—dilated cardiomyopathy	6.44e-05	0.00136	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—ADRB2—dilated cardiomyopathy	6.43e-05	0.00136	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	6.39e-05	0.00135	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—ADRB2—dilated cardiomyopathy	6.36e-05	0.00135	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	6.28e-05	0.00133	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	6.26e-05	0.00133	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—CXCR3—dilated cardiomyopathy	6.25e-05	0.00132	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	6.2e-05	0.00131	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—ADRB1—dilated cardiomyopathy	6.06e-05	0.00128	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—CXCR3—dilated cardiomyopathy	5.99e-05	0.00127	CbGpPWpGaD
Solifenacin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	5.89e-05	0.00125	CbGpPWpGaD
Solifenacin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	5.87e-05	0.00124	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—ADRB1—dilated cardiomyopathy	5.8e-05	0.00123	CbGpPWpGaD
Solifenacin—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	5.73e-05	0.00121	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	5.7e-05	0.00121	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	5.45e-05	0.00116	CbGpPWpGaD
Solifenacin—CHRM1—Regulation of Actin Cytoskeleton—EGFR—dilated cardiomyopathy	5.41e-05	0.00115	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	5.4e-05	0.00114	CbGpPWpGaD
Solifenacin—CHRM3—Regulation of Actin Cytoskeleton—EGFR—dilated cardiomyopathy	5.4e-05	0.00114	CbGpPWpGaD
Solifenacin—CHRM2—Regulation of Actin Cytoskeleton—EGFR—dilated cardiomyopathy	5.34e-05	0.00113	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	5.17e-05	0.0011	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—AGTR1—dilated cardiomyopathy	5.17e-05	0.0011	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	4.99e-05	0.00106	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	4.99e-05	0.00106	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	4.98e-05	0.00105	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	4.98e-05	0.00105	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—AGTR1—dilated cardiomyopathy	4.95e-05	0.00105	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	4.93e-05	0.00104	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	4.93e-05	0.00104	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—ADRB2—dilated cardiomyopathy	4.91e-05	0.00104	CbGpPWpGaD
Solifenacin—CHRM2—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	4.9e-05	0.00104	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—AGT—dilated cardiomyopathy	4.78e-05	0.00101	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—AGT—dilated cardiomyopathy	4.77e-05	0.00101	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—AGT—dilated cardiomyopathy	4.72e-05	0.001	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—ADRB2—dilated cardiomyopathy	4.7e-05	0.000995	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	4.64e-05	0.000983	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	4.63e-05	0.00098	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	4.58e-05	0.000971	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	4.54e-05	0.000961	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	4.54e-05	0.000961	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—AGTR2—dilated cardiomyopathy	4.52e-05	0.000957	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—CXCL2—dilated cardiomyopathy	4.52e-05	0.000957	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	4.5e-05	0.000952	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	4.48e-05	0.000949	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—CXCL2—dilated cardiomyopathy	4.48e-05	0.000948	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—AGTR2—dilated cardiomyopathy	4.48e-05	0.000948	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PSEN2—dilated cardiomyopathy	4.48e-05	0.000948	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	4.44e-05	0.00094	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PSEN2—dilated cardiomyopathy	4.29e-05	0.000908	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	4.22e-05	0.000893	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—CXCR3—dilated cardiomyopathy	4.2e-05	0.00089	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—RAC1—dilated cardiomyopathy	4.2e-05	0.000888	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—CXCR3—dilated cardiomyopathy	4.16e-05	0.000881	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	4.08e-05	0.000865	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—ADRB1—dilated cardiomyopathy	4.07e-05	0.000862	CbGpPWpGaD
Solifenacin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	4.04e-05	0.000855	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—ADRB1—dilated cardiomyopathy	4.03e-05	0.000854	CbGpPWpGaD
Solifenacin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	4.02e-05	0.000852	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—RAC1—dilated cardiomyopathy	4.02e-05	0.000851	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—AGT—dilated cardiomyopathy	4.01e-05	0.000849	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CXCL2—dilated cardiomyopathy	3.97e-05	0.000841	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—AGTR2—dilated cardiomyopathy	3.97e-05	0.000841	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	3.84e-05	0.000813	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—AGT—dilated cardiomyopathy	3.84e-05	0.000813	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	3.83e-05	0.000811	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—RAC1—dilated cardiomyopathy	3.81e-05	0.000807	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—AGTR2—dilated cardiomyopathy	3.81e-05	0.000806	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CXCL2—dilated cardiomyopathy	3.81e-05	0.000806	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	3.79e-05	0.000803	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CXCR3—dilated cardiomyopathy	3.69e-05	0.000782	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—RAC1—dilated cardiomyopathy	3.65e-05	0.000773	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	3.64e-05	0.000772	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—AGT—dilated cardiomyopathy	3.64e-05	0.000771	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	3.63e-05	0.000769	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	3.6e-05	0.000762	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.58e-05	0.000758	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CXCR3—dilated cardiomyopathy	3.54e-05	0.000749	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	3.49e-05	0.000739	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—AGT—dilated cardiomyopathy	3.49e-05	0.000738	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—AGTR1—dilated cardiomyopathy	3.48e-05	0.000736	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—AGTR1—dilated cardiomyopathy	3.44e-05	0.000729	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.43e-05	0.000726	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	3.34e-05	0.000706	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	3.31e-05	0.000701	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—ADRB2—dilated cardiomyopathy	3.3e-05	0.000698	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—ADRB2—dilated cardiomyopathy	3.27e-05	0.000692	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	3.14e-05	0.000664	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.06e-05	0.000647	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PSEN2—dilated cardiomyopathy	3.02e-05	0.000639	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PSEN2—dilated cardiomyopathy	3.01e-05	0.000637	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PSEN2—dilated cardiomyopathy	2.98e-05	0.000631	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.93e-05	0.00062	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.9e-05	0.000614	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	2.84e-05	0.000601	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	2.83e-05	0.000599	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—RAC1—dilated cardiomyopathy	2.82e-05	0.000597	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—RAC1—dilated cardiomyopathy	2.79e-05	0.000591	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.78e-05	0.000588	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—AGT—dilated cardiomyopathy	2.7e-05	0.000572	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—AGT—dilated cardiomyopathy	2.69e-05	0.000571	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CXCL2—dilated cardiomyopathy	2.68e-05	0.000567	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—AGTR2—dilated cardiomyopathy	2.68e-05	0.000567	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CXCL2—dilated cardiomyopathy	2.67e-05	0.000566	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—AGTR2—dilated cardiomyopathy	2.67e-05	0.000566	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—AGT—dilated cardiomyopathy	2.67e-05	0.000565	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—AGTR2—dilated cardiomyopathy	2.64e-05	0.00056	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CXCL2—dilated cardiomyopathy	2.64e-05	0.00056	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—RAC1—dilated cardiomyopathy	2.57e-05	0.000544	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—RAC1—dilated cardiomyopathy	2.56e-05	0.000542	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—RAC1—dilated cardiomyopathy	2.54e-05	0.000537	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.53e-05	0.000535	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.49e-05	0.000527	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CXCR3—dilated cardiomyopathy	2.49e-05	0.000527	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CXCR3—dilated cardiomyopathy	2.48e-05	0.000526	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CXCR3—dilated cardiomyopathy	2.46e-05	0.000521	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—AGT—dilated cardiomyopathy	2.45e-05	0.00052	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—AGT—dilated cardiomyopathy	2.45e-05	0.000518	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—AGT—dilated cardiomyopathy	2.42e-05	0.000513	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.42e-05	0.000512	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—ADRB1—dilated cardiomyopathy	2.41e-05	0.000511	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—ADRB1—dilated cardiomyopathy	2.4e-05	0.000509	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.39e-05	0.000505	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—ADRB1—dilated cardiomyopathy	2.38e-05	0.000504	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—RAC1—dilated cardiomyopathy	2.25e-05	0.000477	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—RAC1—dilated cardiomyopathy	2.16e-05	0.000456	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—AGT—dilated cardiomyopathy	2.15e-05	0.000455	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.06e-05	0.000436	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—AGT—dilated cardiomyopathy	2.06e-05	0.000436	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.05e-05	0.000435	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.03e-05	0.000431	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—GPX1—dilated cardiomyopathy	1.97e-05	0.000417	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.95e-05	0.000414	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.95e-05	0.000413	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.93e-05	0.000409	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—CD36—dilated cardiomyopathy	1.92e-05	0.000407	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.73e-05	0.000367	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—AGT—dilated cardiomyopathy	1.73e-05	0.000366	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—RAF1—dilated cardiomyopathy	1.7e-05	0.000361	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—RAF1—dilated cardiomyopathy	1.7e-05	0.00036	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—RAF1—dilated cardiomyopathy	1.68e-05	0.000356	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.68e-05	0.000356	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.67e-05	0.000355	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.66e-05	0.000351	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.66e-05	0.000351	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—RAC1—dilated cardiomyopathy	1.52e-05	0.000321	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—RAC1—dilated cardiomyopathy	1.51e-05	0.00032	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—RAC1—dilated cardiomyopathy	1.5e-05	0.000317	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—RAF1—dilated cardiomyopathy	1.49e-05	0.000316	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—AGT—dilated cardiomyopathy	1.45e-05	0.000307	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—AGT—dilated cardiomyopathy	1.45e-05	0.000306	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—AGT—dilated cardiomyopathy	1.43e-05	0.000303	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—RAF1—dilated cardiomyopathy	1.43e-05	0.000303	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.17e-05	0.000247	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.16e-05	0.000247	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.15e-05	0.000244	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—EGFR—dilated cardiomyopathy	1.02e-05	0.000217	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—RAF1—dilated cardiomyopathy	1.01e-05	0.000213	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—RAF1—dilated cardiomyopathy	1e-05	0.000212	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—RAF1—dilated cardiomyopathy	9.93e-06	0.00021	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—EGFR—dilated cardiomyopathy	9.8e-06	0.000208	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	7.71e-06	0.000163	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	7.5e-06	0.000159	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—EGFR—dilated cardiomyopathy	6.9e-06	0.000146	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—EGFR—dilated cardiomyopathy	6.88e-06	0.000146	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—EGFR—dilated cardiomyopathy	6.81e-06	0.000144	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	6.76e-06	0.000143	CbGpPWpGaD
